15 assets in T-Cell Childhood Acute Lymphocytic Leukemia

Therapeutic assets addressing T-Cell Childhood Acute Lymphocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Vincristine Sulfate T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (74)
Pegaspargase T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (73)
Dexasone T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (72)
Methotrexate T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (72)
Cyclophosphamide T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (71)
Cytarabine T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (70)
Etoposide T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (70)
Daunomycin T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (68)
Mercaptopurine Anhydrous T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (68)
Adriamycin T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (66)
Hydrocortisone T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (66)
Bortezomib T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BB (64)
Isocyclophosphamide T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	B (60)
Thioguanine Anhydrous T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	B (60)
(+)-Vincristine T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	B (60)